OptiKira raises $3.7 million to develop treatments for blindness

Story excerpt provided by Crain’s Cleveland Business.

Written by Chuck Soder.

Investors have injected $3.7 million into a startup company developing treatments for blindness and other diseases caused by progressive cell death.

OptiKira LLC, a spinoff of Shaker Heights-based BioMotiv, will use the money to continue developing drugs that could be used to treat degenerative eye diseases, according to BioMotiv CEO Baiju Shah.

OptiKira, which is based at BioMotiv’s office, eventually aims to develop drugs for other diseases, such as diabetes and ALS (amyotrophic lateral sclerosis).

Click here to read the complete article.

Originally published August 9, 2016.